Cargando…

High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer

Detalles Bibliográficos
Autores principales:	Kitson, Sarah J., Lindsay, Jennifer, Sivalingam, Vanitha N., Rutter, Martin K., Crosbie, Emma J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262224/ https://www.ncbi.nlm.nih.gov/pubmed/30533477 http://dx.doi.org/10.1016/j.gore.2018.08.006

Ejemplares similares

The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study
por: Kitson, Sarah J., et al.
Publicado: (2018)

Optimization of Window Study Endpoints in Endometrial Cancer
por: Kitson, Sarah J., et al.
Publicado: (2019)

Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2021)

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin
por: Sivalingam, Vanitha N., et al.
Publicado: (2019)

Cardiovascular disease in women diagnosed with endometrial cancer
por: Galazis, N., et al.
Publicado: (2018)

Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome
por: Atiomo, William, et al.
Publicado: (2017)

Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer
por: Latif, Ayşe, et al.
Publicado: (2017)

Prevalence of Lynch Syndrome among Patients with Newly Diagnosed Endometrial Cancers
por: Egoavil, Cecilia, et al.
Publicado: (2013)

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
por: Kitson, Sarah, et al.
Publicado: (2017)

The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study
por: Ryan, Neil A. J., et al.
Publicado: (2020)

The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol
por: Ryan, Neil A. J., et al.
Publicado: (2018)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Measuring the biological effect of presurgical metformin treatment in endometrial cancer
por: Sivalingam, V N, et al.
Publicado: (2016)

Cost-Effectiveness of the Manchester Approach to Identifying Lynch Syndrome in Women with Endometrial Cancer
por: Snowsill, Tristan M., et al.
Publicado: (2020)

Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome
por: Zhao, Hao, et al.
Publicado: (2018)

Prevalence and characteristics of the metabolic syndrome among newly diagnosed hypertensive patients
por: Osuji, Charles U., et al.
Publicado: (2012)

The practice of universal screening for Lynch syndrome in newly diagnosed endometrial carcinoma
por: Wang, Aifen, et al.
Publicado: (2018)

Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer
por: Ryan, Neil A. J., et al.
Publicado: (2020)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors
por: Kitson, Sarah J., et al.
Publicado: (2019)

Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study
por: Paraskevaidi, Maria, et al.
Publicado: (2020)

Institutional factors associated with early mortality of newly diagnosed acute promyelocytic leukemia
por: Matsuda, Kensuke, et al.
Publicado: (2022)

BRCA and lynch syndrome-associated ovarian cancers behave differently
por: Ryan, Neil A.J., et al.
Publicado: (2017)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents
por: Romano, Alessandra, et al.
Publicado: (2017)

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
por: Jonas, Brian A., et al.
Publicado: (2022)

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient
por: Barchi, Virginia, et al.
Publicado: (2022)

High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma
por: Shan, Xinhe, et al.
Publicado: (2023)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma
por: Leng, Siyang, et al.
Publicado: (2020)

Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis
por: Santoni, Adele, et al.
Publicado: (2023)

Prevalence of metabolic syndrome among newly diagnosed hypertensive patients in the hills of Himachal Pradesh, India
por: Thakur, Surender, et al.
Publicado: (2013)

Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer
por: Kim, Soyoun Rachel, et al.
Publicado: (2021)

Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting
por: Snowsill, Tristan M., et al.
Publicado: (2019)

Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK
por: Carr, Matthew J, et al.
Publicado: (2021)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i002h5049g1ma3fkibvohfdpd9